Evaluation of a Polymeric Topical Formulation of Endoxifen in an Estrogen Receptor Positive Breast Cancer Murine Model.

[1]  A. Jager,et al.  The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer , 2023, ESMO open.

[2]  D. Topgaard,et al.  Solubility of Foreign Molecules in Stratum Corneum Brick and Mortar Structure , 2023, Langmuir : the ACS journal of surfaces and colloids.

[3]  J. Cuzick,et al.  Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials , 2022, The Lancet. Oncology.

[4]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[5]  C. Chen,et al.  Berberine-Loaded Thiolated Pluronic F127 Polymeric Micelles for Improving Skin Permeation and Retention , 2020, International journal of nanomedicine.

[6]  J. Rivas-Carrillo,et al.  Selective estrogen receptor modulators in the prevention of breast cancer in premenopausal women: a review , 2020, Translational cancer research.

[7]  P. Rosenberg,et al.  Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data , 2019, British Journal of Cancer.

[8]  Gretchen L. Gierach,et al.  Divergent oestrogen receptor-specific breast cancer trends in Ireland (2004-2013): Amassing data from independent Western populations provide etiologic clues. , 2017, European journal of cancer.

[9]  Amit K. Goyal,et al.  Permeation enhancer strategies in transdermal drug delivery , 2016, Drug delivery.

[10]  N. Hansen,et al.  Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation , 2015, Cancer Chemotherapy and Pharmacology.

[11]  Marius Raica,et al.  The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. , 2015, Anticancer research.

[12]  Z. Iqbal,et al.  Development and evaluation of pluronic- and methylcellulose-based thermoreversible drug delivery system for insulin , 2014, Drug development and industrial pharmacy.

[13]  M. Goetz,et al.  Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies , 2014, Cancer Chemotherapy and Pharmacology.

[14]  Ryan M. Pearson,et al.  Dendron‐Based Micelles for Topical Delivery of Endoxifen: A Potential Chemo‐Preventive Medicine for Breast Cancer , 2014 .

[15]  Anaïs Pitto‐Barry,et al.  Pluronic® block-copolymers in medicine: from chemical and biological versatility to rationalisation and clinical advances , 2014 .

[16]  R. Guy,et al.  Transdermal flux predictions for selected selective oestrogen receptor modulators (SERMs): comparison with experimental results. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[17]  P. Rosenberg,et al.  Divergent estrogen receptor‐positive and ‐negative breast cancer trends and etiologic heterogeneity in Denmark , 2013, International journal of cancer.

[18]  Cesare Oliviero Rossi,et al.  Gels of Pluronic F127 and nonionic surfactants from rheological characterization to controlled drug permeation. , 2011, Colloids and surfaces. B, Biointerfaces.

[19]  Philip S Rosenberg,et al.  Incidence of breast cancer in the United States: current and future trends. , 2011, Journal of the National Cancer Institute.

[20]  T. Fehm,et al.  Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma , 2011, Clinical pharmacology and therapeutics.

[21]  H. Yoo,et al.  Pluronic/chitosan hydrogels containing epidermal growth factor with wound-adhesive and photo-crosslinkable properties. , 2010, Journal of biomedical materials research. Part A.

[22]  Yong Zhang,et al.  PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel , 2010, Comput. Methods Programs Biomed..

[23]  Shaofei Xie,et al.  DDSolver: An Add-In Program for Modeling and Comparison of Drug Dissolution Profiles , 2010, The AAPS Journal.

[24]  S. Sheikh,et al.  Orally administered Endoxifen is a new therapeutic agent for breast cancer , 2010, Breast Cancer Research and Treatment.

[25]  John D. Minna,et al.  Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery , 2009, PloS one.

[26]  Q. Peng,et al.  Thermosetting gel for the delivery of 5-aminolevulinic acid esters to the cervix. , 2008, Journal of pharmaceutical sciences.

[27]  Robert N Hoover,et al.  Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. , 2007, Journal of the National Cancer Institute.

[28]  Jean Claude Chaumeil,et al.  A Review of Poloxamer 407 Pharmaceutical and Pharmacological Characteristics , 2006, Pharmaceutical Research.

[29]  I. Cohen.  Endometrial pathologies associated with postmenopausal tamoxifen treatment. , 2004, Gynecologic oncology.

[30]  O. Pillai,et al.  Transdermal delivery of insulin from poloxamer gel: ex vivo and in vivo skin permeation studies in rat using iontophoresis and chemical enhancers. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[31]  P. Costa,et al.  Evaluation of Mathematical Models Describing Drug Release from Estradiol Transdermal Systems , 2003, Drug development and industrial pharmacy.

[32]  U. Kompella,et al.  Pluronic F127 gel formulations of deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[33]  T Nagai,et al.  Pluronic F-127 gels incorporating highly purified unsaturated fatty acids for buccal delivery of insulin. , 2001, International journal of pharmaceutics.

[34]  M. Dewhirst,et al.  Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  M. Tan,et al.  Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  M H Gail,et al.  Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. , 1999, Journal of the National Cancer Institute.

[37]  M. Morishita,et al.  Enhanced rectal absorption of insulin-loaded Pluronic F-127 gels containing unsaturated fatty acids. , 1999, International journal of pharmaceutics.

[38]  D. Attwood,et al.  Percutaneous Absorption of Indomethacin from Pluronic F127 Gels in Rats , 1995, The Journal of pharmacy and pharmacology.

[39]  T. Johnston,et al.  Sustained-release interleukin-2 following intramuscular injection in rats , 1995 .

[40]  Christopher J. Froelich,et al.  Sustained Delivery of Interleukin-2 from a Poloxamer 407 Gel Matrix Following Intraperitoneal Injection in Mice , 1992, Pharmaceutical Research.

[41]  H. Merker,et al.  Nude Mice Are Not Hairless , 1990 .

[42]  N. Peppas,et al.  A simple equation for the description of solute release. III. Coupling of diffusion and relaxation , 1989 .

[43]  P. Ueland,et al.  Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. , 1988, Cancer research.

[44]  J. Hadgraft,et al.  Drug release from Pluronic F-127 gels , 1986 .

[45]  S. G. Frank,et al.  In vitro release of lidocaine from pluronic F-127 gels , 1981 .

[46]  V. Jordan,et al.  A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. , 1977, The Journal of endocrinology.

[47]  I. R. Schmolka.  Artificial skin. I. Preparation and properties of pluronic F-127 gels for treatment of burns. , 1972, Journal of biomedical materials research.

[48]  C. Vickers.  EXISTENCE OF RESERVOIR IN THE STRATUM CORNEUM. EXPERIMENTAL PROOF. , 1963, Archives of dermatology.

[49]  M. Tomayko,et al.  Determination of subcutaneous tumor size in athymic (nude) mice , 2004, Cancer Chemotherapy and Pharmacology.

[50]  Kristoffer Almdal,et al.  Towards a phenomenological definition of the term ‘gel’ , 1993 .

[51]  C. Booth,et al.  Micellisation and gelation of triblock copoly(oxyethylene/oxypropylene/oxyethylene), F127 , 1992 .

[52]  B. Katzenellenbogen,et al.  Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. , 1984, Cancer research.